InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

Current share price for CUV : $7.640 0.08 (1.06%)+

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$385 Technical Note - Xeroderma Pigmentosum 16 Jan 2023 9:59AM $24.600 $7.630 fallen by 68.98%
$385 afamelanotide Reduces DNA Photodamage in XP 16 Jan 2023 9:56AM $24.600 $7.630 fallen by 68.98%
$385 CLINUVEL Newsletter I - January 2023 10 Jan 2023 10:57AM $23.630 $7.630 fallen by 67.71%
$385 CLINUVEL Newsletter VI - December 2022 23 Dec 2022 11:29AM $21.390 $7.630 fallen by 64.33%
$385 Notification of cessation of securities - CUV 21 Dec 2022 3:35PM $21.310 $7.630 fallen by 64.20%
$385 Presentation - Jefferies London Healthcare Conference 17 Nov 2022 8:53AM $19.490 $7.630 fallen by 60.85%
$385 CLINUVEL Newsletter V - November 2022 9 Nov 2022 9:37AM $19.350 $7.630 fallen by 60.57%
$385 Change of Director's Interest Notice 7 Nov 2022 11:16AM $19.780 $7.630 fallen by 61.43%
$385 Quarterly Activities/Appendix 4C Cash Flow Report Re-issued 31 Oct 2022 10:00AM $18.660 $7.630 fallen by 59.11%
$385 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2022 9:09AM $18.660 $7.630 fallen by 59.11%
$385 Results of Meeting 26 Oct 2022 12:19PM $19.230 $7.630 fallen by 60.32%
$385 Chair Address 26 Oct 2022 10:04AM $18.940 $7.630 fallen by 59.71%
$385 Melbourne Investor Briefing Presentation 21 Oct 2022 9:13AM $18.050 $7.630 fallen by 57.73%
$385 First vitiligo patient enrolled in monotherapy study 20 Oct 2022 9:54AM $18.120 $7.630 fallen by 57.89%
$385 Investor Presentation - Sydney 14 Oct 2022 9:27AM $17.600 $7.630 fallen by 56.65%
$385 Notice of Annual General Meeting/Proxy Form 23 Sep 2022 9:17AM $19.170 $7.630 fallen by 60.20%
$385 Strategic Update V 19 Sep 2022 9:23AM $21.430 $7.630 fallen by 64.40%
$385 Presentation - HC Wainright Global Investment Conference 13 Sep 2022 9:46AM $22.080 $7.630 fallen by 65.44%
$385 Annual General Meeting Date 8 Sep 2022 11:35AM $19.930 $7.630 fallen by 61.72%
$385 CLINUVEL submits label expansion for adolescent EPP patients 5 Sep 2022 9:17AM $19.250 $7.630 fallen by 60.36%
$385 S&P DJI Announces September 2022 Quarterly Rebalance 2 Sep 2022 5:01PM $19.250 $7.630 fallen by 60.36%
$385 CLINUVEL Investor Webinar Financial Results 2022 31 Aug 2022 9:38AM $17.360 $7.630 fallen by 56.05%
$385 Appendix 4G and Corporate Governance Statement 30 Aug 2022 1:17PM $17.170 $7.630 fallen by 55.56%
$385 Revenue Growth Drives CLINUVEL's Full Year Profit 30 Aug 2022 12:58PM $17.200 $7.630 fallen by 55.64%
$385 Dividend/Distribution - CUV 30 Aug 2022 12:25PM $17.170 $7.630 fallen by 55.56%

276 - 300 of 881 results

Page 12 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.